0
0
5/3/23 at 9:39pm
Organization
Barron's
Author
Janet H. Cho
30 words
0
Comments
ImmunoGen reported “significant and clinically meaningful” late-stage trial results of its Elahere treatment among patients with ovarian cancer.
You are the first to view
https://www.barrons.com/articles/immunogen-stock-price-positive-trial-data-c14c5c81
Create an account
or login to join the discussion